Implanet: Revenue Up 23% in H1 2026, U.S. Becomes Top Market
Medical technology company IMPLANET reported a revenue of €7.13 million for the first half of 2026, up 23% year-over-year. This growth accelerated in the second quarter (+27%), driven by the commercial success of the JSS hybrid posterior fixation system launched in partnership with Chinese group Sanyou Medical. The United States has become the leading regional market in Q2, reflecting an international expansion strategy that is beginning to bear fruit.
Accelerated Growth in Q2, Driven by JSS
IMPLANET posted a revenue of €4.10 million in the second quarter of 2026, up 27% from €3.23 million in the same quarter of 2025. This acceleration contrasts with the more moderate growth in the first quarter (+18% to €3.03 million). The Spine Implants activity stood out with an increase of 48%, from €1.88 million to €2.79 million. Ludovic Lastennet, CEO, attributed this performance to 'the commercial strength of the new JSS hybrid posterior fixation system,' whose sales doubled over the period. The medical equipment distribution activity (ultrasonic scalpel SMTP) showed a slight decline of 3% in Q2, to €1.32 million from €1.35 million a year earlier, but increased by 27% over the semester to €2.31 million. Over six months, spine implants generated €4.81 million (+20% year-over-year) and equipment distribution €2.31 million (+27%).
United States Becomes Leading Regional Market
The geographic breakdown reveals an ongoing strategic shift. In the second quarter, the United States generated €1.55 million in revenue, surpassing France (€1.36 million) for the first time, although the French market grew (+18% in Q2, +13% over the semester). In the United States, growth was +54% over the semester at €2.44 million, and +24% in Q2 alone. The 'Rest of the World' region also accelerated, recording +45% in the second quarter at €1.19 million. Over six months, this region represents €2.07 million (+9% year-over-year). The shift in focus towards the United States underscores the success of the commercial investments made across the Atlantic, where IMPLANET has operated a subsidiary since 2013.
Reduced Cash Position, but Visibility Ensured
As of June 30, 2026, IMPLANET has a cash reserve of €1.01 million. The company asserts it is capable of covering its operational financing needs for the next twelve months, relying on its cash consumption forecasts, anticipated commercial developments for 2026 and 2027, and payment facilities granted by Sanyou Medical. North American expansion and product offering enhancement are among the strategic priorities: recruitment of experienced sales personnel in the United States, launch of new ranges (SMTP Quntas), and expansion of the distribution of co-developed products with Sanyou Medical in France, the United States, and Asia, particularly in China.
